Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-10-02
1999-02-23
Mach, D. Margaret M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31445
Patent
active
058744452
ABSTRACT:
The present invention is directed to a new 5HT.sub.2 antagonist, methanol, and its use in the treatment of a number of disease states.
REFERENCES:
patent: 2833775 (1958-05-01), Sperber et al.
patent: 3058979 (1962-10-01), Ullyot et al.
patent: 3194733 (1965-07-01), Yale et al.
patent: 3394131 (1968-07-01), Yale et al.
patent: 3655676 (1972-04-01), Kaiser et al.
patent: 4569941 (1986-02-01), Suh et al.
patent: 4623728 (1986-11-01), Sarges
patent: 4632929 (1986-12-01), Suh et al.
patent: 4701461 (1987-10-01), Suh et al.
patent: 4762842 (1988-08-01), Cohen et al.
patent: 4783471 (1988-11-01), Carr et al.
patent: 4804663 (1989-02-01), Kennis et al.
patent: 4877798 (1989-10-01), Sorensen
patent: 4908369 (1990-03-01), Schechter et al.
patent: 4912117 (1990-03-01), Carr et al.
patent: 4921863 (1990-05-01), Sugimoto et al.
patent: 5021428 (1991-06-01), Carr et al.
patent: 5070087 (1991-12-01), Teng et al.
patent: 5106855 (1992-04-01), McLees et al.
patent: 5112978 (1992-05-01), Molinari
patent: 5134149 (1992-07-01), Carr et al.
patent: 5158952 (1992-10-01), Janssen et al.
patent: 5169096 (1992-12-01), Carr et al.
patent: 5254556 (1993-10-01), Janssen et al.
patent: 5561144 (1996-10-01), Carr et al.
patent: 5618824 (1997-04-01), Schmidt et al.
patent: 5700812 (1997-12-01), Carr et al.
patent: 5700813 (1997-12-01), Carr et al.
patent: 5721249 (1998-02-01), Carr et al.
An electrophysiological investigation of the mechanism of action of the mechanism of action of the 5-ht2 antagonists ritanserin and mdl 28,133a on amphetamine induced slowing of a 1q0 dopamine neurons, abstract of presentation at International Congress on Schizophrenic Research present in Tuscon Arizona on Apr. 21-25, 1991.
Psychopharmacology (1989) 98:45-50: L. Ugedo wt al.
Drugs of the Future vol. 14, No. 5, 1989, pp. 489-490.
Nambu, Keiko et al., Biochemical Pharmacology, vol. 36, No. 10, pp. 1715-1722, 1987.
Dencker, Svan Jonas et al., Disease Management, CNS Drugs, 1996, Nov.:6(5)367-381.
Remington's Pharmaceuticals Sciences, "Sustained-release drug delivery systems", pp. 1687-1688, 18th Edition-1990.
Pharmacology and Toxicology Supplement 1, 1990, 5-7, E. Christensson et al.
Pharmacology and Toxicology Supplement 1, 1990, 12-17, B. Gustaffson et al.
Life Sciences, vol. 47, pp. 2401-2408, J. Frank Nash, 1990.
The Journal of Pharmacology and Experimental Therapeutics, vol. 253, No. 3, 1162-1170.
Journal of Neurochemistry, vol. 54, No. 3, 1990, 1062-1066, Nash et al.
The Journal of Pharmacology and Experimental Therapeutics, vol. 249, No. 3, 673-679, Goldstein et al., 1989.
Psychopharmacology (1989) vol. 99:S18-S27; H.Y. Meltzer.
The Journal of Pharmacology and Experimental Therapeutics, vol. 251:238-246, Meltzer et al., 1989.
4-Aroylpiperidines and Related Carbinols as Potent and Selective Inhibitors of Serotonin 5-HT2 Receptors with Antipsychotic Potential, Abstract of presentation at International Congress on Schizophrenic Research present in Tuscon Arisona on Apr. 21-25, 1991.
CA 112:172341, abstract of EP 319962, 1989.
CA 106:156281, abstract of EP 208235, 1987.
CA 116:194161, abstract of WO 9118603, 1991.
CA 113:126623, abstract of EP 337136, 1989.
Carr Albert A.
Hay David A.
Kane John M.
Schmidt Christopher J.
M. Mach D. Margaret
Merrell Pharmaceutical, Inc.
Moon, Esq. Carolyn D.
LandOfFree
(+) -.alpha.- (2,3-dimethoxyphenyl)-1-(2-(4-fluorephenyl) ethyl) does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with (+) -.alpha.- (2,3-dimethoxyphenyl)-1-(2-(4-fluorephenyl) ethyl), we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and (+) -.alpha.- (2,3-dimethoxyphenyl)-1-(2-(4-fluorephenyl) ethyl) will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-307345